Literature DB >> 29694669

The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.

Abdulkadir Ercaliskan1, A Emre Eskazan2.   

Abstract

Although the majority of patients with chronic myeloid leukemia do well with treatment with tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many factors that might play a part, including the different BCR-ABL1 transcript types at baseline. The current study was performed to determine the possible impact of different transcripts on the treatment responses and outcomes of patients with chronic myeloid leukemia who are receiving TKI therapy. The authors performed a systematic literature search by using the terms "b2a2/b3a2," "e13a2/e14a2," or "transcript type." e14a2 was the more common transcript type. The majority of the studies demonstrated no significant difference regarding age, sex, leukocyte counts, and hemoglobin levels between patients with the e13a2 and e14a2 transcripts. However, in approximately one-half of the studies, the e14a2 transcript was associated with higher platelet counts. Almost no studies demonstrated a significant association between disease risk scores and transcript types. In the majority of studies, having the e14a2 transcript was associated with earlier, deeper, and higher molecular response rates. Although better event-free survival was observed in patients with the e14a2 transcript in some of the studies, the majority demonstrated that transcript type did not have an impact on progression-free and overall survival. Treatment-free remission currently is a topic of much interest, and to the authors' knowledge there are limited data with conflicting results regarding the possible effects of transcript types on the outcomes of patients after discontinuation of TKIs. Because having the e14a2 transcript appears to be related to a favorable outcome, choosing second-generation TKIs for frontline therapy might be a convenient approach in patients with chronic myeloid leukemia with the e13a2 transcript. The authors believe this finding warrants further investigation.
© 2018 American Cancer Society.

Entities:  

Keywords:  BCR-ABL1; chronic myeloid leukemia (CML); e13a2; e14a2; response; transcript; tyrosine kinase inhibitor (TKI)

Mesh:

Substances:

Year:  2018        PMID: 29694669     DOI: 10.1002/cncr.31408

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

Authors:  Tariq I Mughal; Bethan Psaila; Daniel J DeAngelo; Giuseppe Saglio; Richard A Van Etten; Jerald P Radich
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

2.  Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia.

Authors:  Graeme Greenfield; Ross McMullan; Nuala Robson; Julie McGimpsey; Mark Catherwood; Mary Frances McMullin
Journal:  BMC Hematol       Date:  2019-05-02

3.  Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.

Authors:  Kangkang Chen; Yingying Ruan; Kewei Tian; Peisheng Xiong; Nan Xia; Jin Li; Wen Huang; Feiyan Cao; Qifeng Chen
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

4.  Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.

Authors:  Yi-Jiun Su; Ming-Chung Kuo; Tsai-Yun Chen; Ming-Chung Wang; Youngsen Yang; Ming-Chun Ma; Tung-Liang Lin; Tung-Huei Lin; Hung Chang; Chieh-Lin Jerry Teng; Pei-Ching Hsiao; Chih-Cheng Chen; Po-Nan Wang; Lee-Yung Shih
Journal:  Cancer Sci       Date:  2022-08-17       Impact factor: 6.518

5.  Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts.

Authors:  Michele Massimino; Elena Tirrò; Stefania Stella; Livia Manzella; Maria Stella Pennisi; Chiara Romano; Silvia Rita Vitale; Adriana Puma; Cristina Tomarchio; Sandra Di Gregorio; Agostino Antolino; Francesco Di Raimondo; Paolo Vigneri
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

6.  Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.

Authors:  Selin Kucukyurt; Yeliz Yagiz Ozogul; Abdulkadir Ercaliskan; Levent Kabasakal; Ahmet Emre Eskazan
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.